
Dr Reddy's Laboratories rose 5.9% from $13.96 to $14.79, behind the S&P 500's +10.0%. Its worst day was Jul 22 (−9.4%), and its low came Jul 22 at $11.38.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.16 beat the $0.16 estimate on $978.8M revenue (est. $978.1M).
+0.2% · S&P 500 −2.0%
Dr Reddy's Laboratories shares rose 5.8%, while the S&P 500 fell 0.4%.
Story events cover the past 12 months · Times ET
+5.8%, the year's best day, on 8M shares, the year's heaviest volume · S&P 500 −0.4%
EPS of $0.03 missed the $0.09 estimate on $821.8M revenue (est. $866.1M).
−5.2% · S&P 500 −0.2%
Dr Reddy's Laboratories closed at its highest level of the year, 10.2% above where the year started.
+0.9% · S&P 500 −0.7%
Dr Reddy's Laboratories shares fell 5.0%, while the S&P 500 rose 0.4%.
−5.0% · S&P 500 +0.4%
EPS of $0.06 missed the $0.17 estimate on $853.0M revenue (est. $925.5M).
−9.4%, the year's worst day · S&P 500 −0.1%
Dr Reddy's Laboratories shares rose 4.4%, while the S&P 500 rose 0.9%.
+4.4% · S&P 500 +0.9%
EPS of $0.12 missed the $0.16 estimate on $905.0M revenue (est. $980.6M).
−0.2% · S&P 500 −0.5%
Where it ended: a close of $14.79 on Nov 17, 2026. Up next: Q3 2027 earnings on Jan 19, 2027 (EPS est. $0.15, revenue est. $982.7M).
As of the Nov 17, 2026 close
Replay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RDY and SPY from Benzinga historical bars. Not investment advice.